Daniela Comegna

Daniela Comegna

Auto-generated profile, based on publicly available information

Daniela Comegna

Institute of Biostructures and Bioimaging, CNR, 80134 Naples, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2019 in Cancers
Verified
Journal Article
Open access
PDF file
BHBilly Samuel Hill
Billy Samuel Hill
ASAnnachiara Sarnella
Annachiara Sarnella
Domenica CapassoDomenica Capasso
Domenica Capasso
DCDaniela Comegna
Daniela Comegna
Annarita Del GattoAnnarita Del Gatto
Annarita Del Gatto
AZAntonella Zannetti
Antonella Zannetti
The mesenchymal sub-type of triple negative breast cancer (MES-TNBC) has a highly aggressive behavior and worse prognosis, due to its invasive and stem-like features, that correlate with metastatic dissemination and resistance to therapies. Furthermore, MES-TNBC is characterized by the expression of molecular markers related to the epithelial-to-mesenchymal transition (EMT) program and cancer stem cells (CSCs). The altered expression of αvβ3 integrin has been well established as a driver of cancer progression, stemness, and metastasis. Here, we showed that the high levels of αvβ3 are associated with MES-TNBC and therefore exploited the possibility to target this integrin to reduce the aggressiveness of this carcinoma. To this aim, MES-TNBC cells were treated with a novel peptide, named ψRGDechi, that we recently developed and characterized for its ability to selectively bind and inhibit αvβ3 integrin. Notably, ψRGDechi was able to hamper adhesion, migration, and invasion of MES-TNBC cells, as well as the capability of these cells to form vascular-like structures and mammospheres. In addition, this peptide reversed EMT program inhibits mesenchymal markers. These findings show that targeting αvβ3 integrin by ψRGDechi, it is possible to inhibit some of the malignant properties of MES-TNBC phenotype.

3 November 2011 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
DCDaniela Comegna
Daniela Comegna
MDMarina DellaGreca
Marina DellaGreca
MIM. Rosaria Iesce
M. Rosaria Iesce
LPLucio Previtera
Lucio Previtera
Armando ZarrelliArmando Zarrelli
Armando Zarrelli
Simona ZuppoliniSimona Zuppolini
Simona Zuppolini
3- or 4-Aroylfurans have been prepared selectively and in high yields from a common precursor by simple tuning of reaction conditions in Friedel–Crafts acylation promoted by triflic anhydride. The formation of products can be explained on the basis of the ring-chain tautomerism occurring in compounds equipped with two neighbouring carboxylic functions. Since 4-aroylfuran derivatives show a typical lignan backbone, suitable hydrogenation conditions were found out to gain tetrahydrofuran lignans.

19 September 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Domenica CapassoDomenica Capasso
Domenica Capasso
Annarita Del GattoAnnarita Del Gatto
Annarita Del Gatto
DCDaniela Comegna
Daniela Comegna
Luigi RussoLuigi Russo
Luigi Russo
RFRoberto Fattorusso
Roberto Fattorusso
Laura ZaccaroLaura Zaccaro
Laura Zaccaro
Recently, the research community has become increasingly concerned with the receptor αvβ5, a member of the well-known integrin family. Different ongoing studies have evidenced that αvβ5 integrin regulates not only physiological processes but also a wide array of pathological events, suggesting the receptor as a valuable biomarker to specifically target for therapeutic/diagnostic purposes. Remarkably, in some tumors the involvement of the receptor in cell proliferation, tumor dissemination and angiogenesis is well-documented. In this scenario, the availability of a selective αvβ5 antagonist without ‘off-target’ protein effects may improve survival rate in patients with highly aggressive tumors, such as hepatocellular carcinoma. We recently reported a cyclic peptide, RGDechi15D, obtained by structure-activity studies. To our knowledge it represents the first peptide-based molecule reported in the literature able to specifically bind αvβ5 integrin and not cross react with αvβ3. Here we demonstrated the ability of the peptide to diminish both adhesion and invasion of HepG2 cells, an in vitro model system for hepatocellular carcinoma, to reduce the cell proliferation through an apoptotic process, and to interfere with the PI3K pathway. The peptide, also decreases the formation of new vessels in endothelial cells. Taken together these results indicate that the peptide can be considered a promising molecule with properties suited to be assessed in the future for its validation as a selective therapeutic/diagnostic weapon in hepatocarcinoma.


31 May 2019 in Organic Letters
Verified
Journal Article
Closed access
DCDaniela Comegna
Daniela Comegna
AGAnnarita Del Gatto
Annarita Del Gatto
MSMichele Saviano
Michele Saviano
Laura ZaccaroLaura Zaccaro
Laura Zaccaro